Vir Biotechnology, Inc. (VIR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$11.77+4.90%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · VIR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -51.6% |
| Our one-year growth estimate | diamond | -70.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 19.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
VIR — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-10-14
Unregistered Sales of Equity Securities. On October 9, 2026, Vir Biotechnology, Inc. (Vir Bio) and Gilead Sciences, Inc. (Gilead) entered into a Collaboration and License Agreement (the Agreement), pursuant to which Vir Bio and Gilead will enter into a global strategic collaboration to discover and engineer three novel PRO-XTEN ® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens. Concurrently with the execution of the Agreement, Vir Bio…
Why it matters: These trials test the treatment in different CHD groups. Their results can add support for a broad treatment path.
Watch forBoth trials report data in Q1 2027, and the results meet their stated efficacy and safety goals.
Also watch forEither trial misses its stated goals, raises safety concerns, or reports after Q1 2027.
Why it matters: Vir is loss-making, so cash helps fund its trials. The Gilead deal adds cash, but trial costs remain a key check.
Worry ifThe Nov. 4 update keeps the cash runway into the second half of 2028 or longer, with cash and investments above $1.0 billion.
Less concerning ifThe Nov. 4 update shortens the runway to before the second half of 2028 or reports cash and investments below $1.0 billion.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$221 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $544 loss on $10,000 · 5.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,561 loss on $10,000 · 25.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.